BioSpace News Archive

A preliminary injunction preventing the marketing and sale of Aegis Spine, Inc.’s AccelFix-XT line of expandable medical devices is now in effect

The U.S. Food and Drug Administration today announced it has issued an emergency use authorization (EUA) for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.

Stanford Children’s Health once again is ranked as a national leader for pediatric organ transplantation, according to recent data from the Scientific Registry of Transplant Recipients.

Michelson Medical Research Foundation and the Human Vaccines Project are now welcoming applications for the 2021 Michelson Prize: Next Generation Grants.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date.

nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully completed filing of a second Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its first proprietary soft tissue repair device, Exogenesis Hernia Mesh

CSols, Inc. and Abbott Informatics announce a joint webinar to be presented Wednesday April 21, 2021 at 2 PM EDT with Karla Paulson, Senior Project Manager, Abbott Informatics, and Tuan Nguyen, Senior LIMS Consultant, CSols, Inc.

Prognos Health, a leading healthcare analytics platform company, today announced that its proprietary technology FACTOR Logic™ – the lightning-fast data store technology with which the prognosFACTORⓇ platform is built – is now patent pending.

Boosting its leadership pool as it moves into full growth mode, Carmel-based medical device company PathogenX has named tech entrepreneur Jamie Moriarty to its board of directors. The company also announced that former McKesson Corporation sales standout Robert Gurecka has been named National Sales Director and will lead business development, sales and marketing for the company’s North American efforts.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that on April 5, 2021 it completed its underwritten public offering of common stock, resulting in gross proceeds to Humanigen of approximately $92.5 million.